IE42766L - Pharmaceutical preparations - Google Patents
Pharmaceutical preparationsInfo
- Publication number
- IE42766L IE42766L IE760011A IE1176A IE42766L IE 42766 L IE42766 L IE 42766L IE 760011 A IE760011 A IE 760011A IE 1176 A IE1176 A IE 1176A IE 42766 L IE42766 L IE 42766L
- Authority
- IE
- Ireland
- Prior art keywords
- radical
- compound
- ring
- salt
- used pharmaceutically
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- ANFXTILBDGTSEG-UHFFFAOYSA-N 1-methyl-4,5-dihydroimidazole Chemical compound CN1CCN=C1 ANFXTILBDGTSEG-UHFFFAOYSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- -1 N - substituted dibenzazepine Chemical class 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003133 ergot alkaloid Drugs 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1510370 Compositions for treating coronary heart disease CIBA - GEIGY AG 31 Dec 1975 [6 Jan 1975] 53300/75 Heading A5B Pharmaceutical preparations for the treatment of coronary heart disease contain (1) a beta - receptor blocking compound of the formula:- wherein Ar 1 represents a monocyclic or polycyclic, carbocyclic or heterocyclic radical which contains at least one ring of aromatic character, and which is 'bonded to the oxygen atom via a ring carbon atom, preferably of the ring of aromatic character R 1 denotes an optionally substituted aliphatic, cycloaliphatic or araliphatic hydrocarbon radical and R 2 represents hydrogen or the acyl radical of an organic carboxylic acid, or a compound of the formula wherein R 1 and R 2 have the abovementioned meanings, Ar 2 represents a monocyclic or polycyclic, carbocyclic radical which contains at least one ring of aromatic character, and R 3 denotes hydrogen or lower alkyl, or a salt of such compounds which can be used pharmaceutically, (2) a compound which regulates the thrombocyte function which is acetylsalicylic acid or a salt thereof with a base which can be used pharmaceutically, 2, 6 - bis- [di - (2 - hydroxyethyl) - amino] - 4, 8 - di - piperidino - pyrimido [5, 4 - d] pyrimidine, or an acid addition salt thereof which can be used pharmacetically or a compound of the formula wherein each of the radicals Ph 1 and Ph 2 independently of one another represents a phenyl radical which is optionally substituted by lower alkyl, hydroxyl, lower alkoxy and/or halogen, Alk denotes a lower alkylene radical which separates the sulphur atom from the ring carbon atom by at least 2 carbon atoms, n represents 0, 1 or 2 and Ph 3 represents a phenyl radical which is optionally substituted by lower alkyl, lower alkoxy and/or halogen, or a salt thereof with a base, which can be used pharmacologically, and optionally (3), an alpha - receptor blocking compound which is a hydrogenated ergot alkaloid, or a mixture of such alkaloids or acid addition salts thereof which can be used pharmaceutically, or a N - benzyl - N - halogeno - lower alkylamine, a 2 - tert. - aminomethyl - benzodioxane, a N - substituted dibenzazepine or a methyl - 2 - imidazoline which is substituted in the 2 - position or acid addition salts of such compounds which can be used pharmaceutically.
[GB1510370A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH7175 | 1975-01-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE42766L true IE42766L (en) | 1976-07-06 |
| IE42766B1 IE42766B1 (en) | 1980-10-08 |
Family
ID=4178628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE11/76A IE42766B1 (en) | 1975-01-06 | 1976-01-05 | Pharmaceutical preparations for the treatment of coronary heart diseases |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS5191337A (en) |
| AU (1) | AU499140B2 (en) |
| BE (1) | BE837293A (en) |
| CA (1) | CA1063516A (en) |
| DE (1) | DE2600069A1 (en) |
| FR (1) | FR2296430A1 (en) |
| GB (1) | GB1510370A (en) |
| HK (1) | HK49680A (en) |
| IE (1) | IE42766B1 (en) |
| IL (1) | IL48785A (en) |
| MY (1) | MY8100159A (en) |
| NL (1) | NL7600045A (en) |
| NZ (1) | NZ179623A (en) |
| ZA (2) | ZA7628B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0019006A1 (en) * | 1979-05-14 | 1980-11-26 | Ciba-Geigy Ag | Pharmaceutical preparations containing a substituted pyrazolidine derivative as active substance, their application and manufacturing process |
| FR2470599A1 (en) * | 1979-12-07 | 1981-06-12 | Panoz Donald | IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED |
| TW284688B (en) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL37700A (en) * | 1970-10-02 | 1975-05-22 | Ciba Geigy Ag | Pharmaceutical preparations containing an aryloxypropanolamine derivative or an arylethanolamine derivative |
-
1975
- 1975-12-22 NZ NZ179623A patent/NZ179623A/en unknown
- 1975-12-31 GB GB53300/75A patent/GB1510370A/en not_active Expired
-
1976
- 1976-01-02 CA CA242,899A patent/CA1063516A/en not_active Expired
- 1976-01-02 DE DE19762600069 patent/DE2600069A1/en not_active Withdrawn
- 1976-01-02 FR FR7600016A patent/FR2296430A1/en active Granted
- 1976-01-05 AU AU10002/76A patent/AU499140B2/en not_active Expired
- 1976-01-05 IE IE11/76A patent/IE42766B1/en unknown
- 1976-01-05 IL IL48785A patent/IL48785A/en unknown
- 1976-01-05 ZA ZA00760028A patent/ZA7628B/en unknown
- 1976-01-05 ZA ZA00760026A patent/ZA7626B/en unknown
- 1976-01-05 NL NL7600045A patent/NL7600045A/en not_active Application Discontinuation
- 1976-01-05 BE BE163295A patent/BE837293A/en unknown
- 1976-01-06 JP JP51000124A patent/JPS5191337A/ja active Pending
-
1980
- 1980-09-04 HK HK496/80A patent/HK49680A/en unknown
-
1981
- 1981-12-30 MY MY159/81A patent/MY8100159A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ179623A (en) | 1978-03-06 |
| IL48785A (en) | 1978-08-31 |
| AU1000276A (en) | 1977-07-14 |
| HK49680A (en) | 1980-09-12 |
| NL7600045A (en) | 1976-07-08 |
| MY8100159A (en) | 1981-12-31 |
| AU499140B2 (en) | 1979-04-05 |
| IL48785A0 (en) | 1976-03-31 |
| BE837293A (en) | 1976-07-05 |
| CA1063516A (en) | 1979-10-02 |
| IE42766B1 (en) | 1980-10-08 |
| JPS5191337A (en) | 1976-08-10 |
| ZA7626B (en) | 1976-12-29 |
| FR2296430B1 (en) | 1978-11-10 |
| ZA7628B (en) | 1976-12-29 |
| DE2600069A1 (en) | 1976-07-15 |
| FR2296430A1 (en) | 1976-07-30 |
| GB1510370A (en) | 1978-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO164980C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE CARBAPENNAM DERIVATIVES. | |
| NO882608D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PYRAZOLOPYRIDEIRS. | |
| IL103944A0 (en) | Piperazine derivatives,their preparation and pharmaceutical compositions containing them | |
| NO163855C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ARYLYCYLOBUTYLALKYLAMINES. | |
| DE3855325D1 (en) | Oxothiolanes and derivatives, pharmaceutical preparations containing them and their use as medicines | |
| GB9215844D0 (en) | Novel compounds | |
| NO881835L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BICYCLIC RELATIONS. | |
| EP0206616A3 (en) | Quinolones having antihypertensive activity | |
| GB1510370A (en) | Pharmaceutical preparations for the treatment of coronary heart diseases | |
| SE8800171D0 (en) | NEW 5-OXY DERIVATIVES OF TETRAHYDROFURAN | |
| JPS57154129A (en) | Cardiotonic drug | |
| HUT50176A (en) | Process for production of derivatives of heterocyclic lactane and medical compositions containing them as active substance | |
| ATE27455T1 (en) | HETEROCYCLIC GUANIDINO-PHENYLAMIDINES, PROCESSES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE. | |
| SE8802997L (en) | AMINERY DERIVATIVES AND ITS SALT, PROCEDURES FOR PREPARING THEREOF AND Means against their containing |